Our highly sensitive Hereditary Ovarian Cancer Panel analyzes 21 genes, covering all high penetrance genes as well as other high and medium risk genes that have well-established evidence of association with melanoma.
Genes Analyzed
| BARD1 | BRCA1 | BRCA2 | BRIP1 | CDH1 | CHEK2 | DICER1 |
| EPCAM | MLH1 | MRE11A | MSH2 | MSH6 | NBN | PALB2 |
| PMS2 | PAD50 | RAD51C | PAD51D | SMARCA4 | STK11 | TP53 |
Ovarian cancer is the second most common gynecologic cancer in the United States. 1 in 70 women in the US will develop ovarian cancer during their lifetime. Among the patients who are diagnosed with ovarian cancer, over 15% of patients have a germline BRCA mutation. In addition to BRCA1 and BRCA2, other high penetrance genes like BRIP1 and MSH6 have a well-established association with hereditary ovarian cancer. Individuals with a pathogenic variant in any of these genes have a significantly increased risk of developing ovarian cancer.
Lifetime Cancer Risks
Who Should Get Tested?
Certain red flags indicate a higher risk for hereditary ovarian cancer, which include but are not limited to:
- Ovarian cancer at an early age.
- Uterine cancer diagnosed at an early age or with an abnormal MSI gene.
- Multiple primary cancers in one person.
- Close family members with ovarian, breast, uterine or certain other cancers.
.png){kind=logo}